Article
Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated Waldenström macroglobulinemia.
Blood - 28 Oct 2021
Treon Steven P, Meid Kirsten, Hunter Zachary R, Flynn Catherine A, Sarosiek Shayna R, Leventoff Carly R, White Timothy P, Cao Yang, Roccaro Aldo M, Sacco Antonio, Demos Maria G, Guerrera Maria Luisa, Kofides Amanda, Liu Xia, Xu Lian, Patterson Christopher J, Munshi Manit, Tsakmaklis Nicholas, Yang Guang, Ghobrial Irene M, Branagan Andrew R, Castillo Jorge J
Abstract excerpt
MYD88 and CXCR4 mutations are common in Waldenström macroglobulinemia (WM). Mutated CXCR4 (CXCR4Mut) impacts BTK-inhibitor response. We conducted a phase 1 trial of the CXCR4-antagonist ulocuplumab with ibrutinib in this first-ever study to target CXCR4Mut in WM. Ibrutinib was initiated at 420 mg/d with cycle 1 and continued until intolerance or progression; ulocuplumab was given cycles 1 to 6, with a 3 + 3...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.